Does nebivolol have renoprotective action in patients with chronic kidney disease conditions? An integrative review.
Eur J Pharmacol
; 905: 174180, 2021 Aug 15.
Article
in En
| MEDLINE
| ID: mdl-34015319
ABSTRACT
Systemic arterial hypertension (SAH) is a chronic disease of multifactorial origin and one of the main risk factors for major adverse cardiovascular events (MACE), which are the leading causes of morbidity and mortality worldwide. The pharmacological treatment of SAH involves five main classes of drugs, and Nebivolol (NEB) is one of those drugs, belonging to the class of third generation ß1-adrenoceptors selective blockers. NEB is composed of a racemic mixture of two enantiomers d-nebivolol, which exerts antagonist effects on ß1-adrenoceptors, and l-nebivolol, a vascular ß3 receptor agonist. There are several studies that report different actions of NEB, not only for the treatment of SAH, but also as an antioxidant agent or even as a protector of renal damage. The aim of this systematic review was to investigate the available evidence regarding the effects of NEB on kidney diseases, evaluating its possible renoprotective action.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Protective Agents
/
Renal Insufficiency, Chronic
/
Nebivolol
Type of study:
Risk_factors_studies
/
Systematic_reviews
Limits:
Animals
/
Humans
Language:
En
Journal:
Eur J Pharmacol
Year:
2021
Document type:
Article
Affiliation country:
Brazil